SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing a surge in community interest driven by its technological focus on quantum-resistant security and its potential role in real-world asset (RWA) tokenization. Investors are actively debating the long-term institutional utility of the protocol, with many pointing to recent ecosystem developments and potential regulatory catalysts as signs of an upcoming turnaround.

Ciena Corp. is a network technology company, which engages in the provision of hardware, software, and services to network operators, as well as enabling enhanced network capacity, service delivery, and automation. It operates through the following segments: Networking Platforms, Platform Software and Services, Blue Planet Automation Software and Services, and Global Services. The Networking Platforms segment consists of converged packet optical and packet networking portfolios. The Platform Software and Services segment provides analytics, data, and planning tools to assist customers in managing its networking platforms products. The Blue Planet Automation Software and Services segment enables customers to implement large-scale software and IT-led OSS transformations by transforming legacy networks into service ready networks. The Global Services segment offers a broad suite of value-added services. The company was founded by Patrick H. Nettles and Kevin Brian Kimberlin in 1992 and is headquartered in Hanover, MD.

CIENA Corp.

Ciena is gaining strong momentum as investors increasingly view the company as a critical backbone for AI-driven data center infrastructure and high-speed network expansion. The community is actively debating the stock's parabolic trajectory and aggressive valuation, with many traders closely watching for technical signals while balancing bullish long-term thesis on photonics against potential volatility risks.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently the center of active community debate as shareholders press for strategic changes, driven by activist pressure from Shah Capital and speculation regarding leadership stability following recent executive departures. Investors are closely monitoring the stock for signs of a potential buyout or major partnership, while sentiment remains polarized between those anticipating a volatility-driven breakout and others frustrated by the stock's persistent price suppression.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph (HBAR) is currently generating buzz as investors monitor potential regulatory catalysts like the CLARITY Act, which some believe could provide institutional clarity and trigger a significant price re-rating. While retail sentiment remains cautious and polarized over token dilution and price performance, the community is closely tracking institutional accumulation, recent exchange listings, and the integration of Hedera's ledger technology by major enterprise partners.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The DAX is currently trending as investors scrutinize its technical structure and price action following recent volatility, with the community actively debating whether the index is establishing a long-term bottom or facing deeper corrective risks. Discussion is heavily focused on Elliott Wave signals, anchored VWAP support levels, and the broader macro implications of energy costs and industrial shifts within the German market.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF (VTI) is trending as retail investors engage in intense debates regarding the potential impact of escalating geopolitical tensions in the Middle East and domestic political instability on the broader US markets. Community discussion remains heavily polarized, with many users weighing the risks of prolonged market volatility against the conviction that a simplified, long-term buy-and-hold strategy remains the most effective defense against current macro uncertainty.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting strong Phase 3 clinical trial data, with community members actively debating the drug's potential to establish itself as a new gold standard in treating inflammatory skin conditions. Investors are intensely focused on the implications for future M&A activity, with many highlighting the data's competitive edge while others monitor institutional accumulation and potential short-covering catalysts.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is currently drawing significant investor attention as momentum builds around its role in the defense and aerospace supply chain, highlighted by recent high-profile contract wins and significant insider debt-to-equity conversions. The community is actively debating the company's long-term potential as a critical infrastructure provider for entities like SpaceX and the Department of Defense, while closely watching for further partnership updates and financial milestones.

Shift4 Payments, Inc. is an independent provider, which engages in the provision of payment acceptance and payment processing technology solutions in the U.S. based on total volume of payments processed. It operates through the U.S. and International geographical segments. The company was founded by Jared Isaacman in 1999 and is headquartered in Center Valley, PA.

Shift4 Payments Inc - Ordinary Shares - Class A

Shift4 Payments is currently trending due to a combination of strong institutional interest, including active insider buying by the founder, and persistent speculation regarding potential takeover interest from larger fintech players or a possible privatization. Despite recent price volatility and concerns about debt levels, retail investors are intensely focused on the company's aggressive stock buyback program and its perceived long-term undervaluation relative to its high growth profile.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software Inc is facing significant market volatility as investors debate the impact of AI on its core game engine business, leading to heavy short interest and speculation regarding potential acquisition activity. The community is actively tracking upcoming product demonstrations at the Game Developers Conference for signs of a turnaround, with many bulls viewing current price levels as a generational buying opportunity despite concerns over the broader software sector's performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Sell Stocks for April 2nd

ACCO, CDE and EPRX have been added to the Zacks Rank #5 (Strong Sell) List on April 2nd, 2026.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 26.3% in March

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 2,500,950 shares, an increase of 26.3% from the February 26th total of 1,979,996 shares. Approximately...

Eupraxia Pharmaceuticals (EPRX) to Release Earnings on Tuesday

Eupraxia Pharmaceuticals (NASDAQ:EPRX) will be releasing earnings before the market opens on Tuesday, March 31. (View Earnings Report at...

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.read more...

William Blair Initiates Coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX)

William Blair assumed coverage on shares of Eupraxia Pharmaceuticals in a report on Monday. They issued an "outperform" rating for the company...

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Announces Earnings Results, Misses Estimates By $0.21 EPS

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.21...

Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Lowered by Zacks Research

Zacks Research downgraded Eupraxia Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Tuesday...

Lifesci Capital Has Negative Outlook of EPRX FY2026 Earnings

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Analysts at Lifesci Capital dropped their FY2026 earnings per share estimates for shares of Eupraxia Pharmaceuticals in a research note issued to investors on Monday, March 16th. Lifesci Capital analyst S. Slutsky now forecasts that the com...

What is HC Wainwright's Estimate for EPRX Q1 Earnings?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Eupraxia Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 17th. HC Wainwright analyst B. Folkes forecasts that t...

Q2 Earnings Estimate for EPRX Issued By HC Wainwright

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of Eupraxia Pharmaceuticals in a report released on...

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell, John Salvatore Montalbano and Amanda Malone on May 12, 2011 and is headquartered in Victoria, Canada.

Eupraxia Pharmaceuticals Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Current Price	$7.17
Prev Close	$7.33
Open	$7.13
Dividend Yield	0.00%
50-Day Moving Average	$7.97
Beta	0.61
Avg. Volume	231,875.53
PE Ratio	-7.23

52-Week High	$9.32
52-Week Low	$2.68
Market Capitalization	$440.98M
EPS (Annual)	-$1.03
Price to Book	7.12
Revenue Per Employee	N/A

EPRX
Eupraxia Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest EPRX News

EPRXEupraxia Pharmaceuticals Inc